F. Hoffmann-La Roche AG


About Roche

Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare – a strategy that aims to fit the right treatment to each patient in the best way possible.

Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management.

Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. The company also aims to improve patient access to medical innovations by working with all relevant stakeholders. More than thirty medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and cancer medicines. Moreover, for the eleventh consecutive year, Roche has been recognised as one of the most sustainable companies in the Pharmaceuticals Industry by the Dow Jones Sustainability Indices (DJSI).

The Roche Group, headquartered in Basel, Switzerland, is active in over 100 countries and in 2019 employed about 98,000 people worldwide. In 2019, Roche invested CHF 11.7 billion in R&D and posted sales of CHF 61.5 billion. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit www.roche.com.

Roche retains sole responsibility for content © 2020 F. Hoffmann-La Roche AG. All trademarks used or mentioned in this release are protected by law.

1 June 2019 - 31 May 2020

Region: Global
Subject/journal group: All

The table to the right includes counts of all research outputs for F. Hoffmann-La Roche AG published between 1 June 2019 - 31 May 2020 which are tracked by the Nature Index.

Hover over the donut graph to view the FC output for each subject. Below, the same research outputs are grouped by subject. Click on the subject to drill-down into a list of articles organized by journal, and then by title.

Note: Articles may be assigned to more than one subject area.

Count Share
169 61.20

Outputs by subject (Share)

Subject Count Share
Life Sciences 144 45.38
1 0.17
6 4.18
4 2.22
2 0.50
1 0.04
1 0.25
1 0.03
3 1.63
2 1.92
7 0.40
6 1.47
4 2.93
5 1.55
4 0.02
10 4.17
1 0.07
3 0.34
25 3.78
1 0.48
4 0.73
10 1.73
1 0.21
2 1.41
Global site-specific neddylation profiling reveals that NEDDylated cofilin regulates actin dynamics
Negative regulation of RAF kinase activity by ATP is overcome by 14-3-3-induced dimerization
1 0.03
1 0.39
2 0.30
9 3.93
6 2.23
3 0.76
5 3.02
1 0.05
12 4.46
Chemistry 33 18.40
Physical Sciences 4 0.80
Earth & Environmental Sciences 1 0.50

Highlight of the month

Cobra genome sequenced in search for new antivenoms

© Capt Suresh Sharma/Getty

© Capt Suresh Sharma/Getty

A complete genome map from one of the world’s deadliest snakes could help develop new treatments for snakebite victims.

Globally, about 100,000 people die from snakebites each year. Antivenoms have been developed, but they can be costly to produce.

A team led by scientists at Genentech, a Roche subsidiary, has decoded all 38 chromosomes of the Indian cobra, one of the ‘big four’ species responsible for the most snakebite-related deaths on the Indian subcontinent.

The researchers identified around 23,000 protein-coding genes, around half of which were actively expressed in the snake’s venom glands. Of these, 19 were directly responsible for producing the poisonous brew of toxins, enzymes, growth factors and other proteins that can collectively kill or disable anyone unlucky enough to encounter the cobra’s bite.

With this catalogue of venom-specific genes, the researchers hope to begin developing next-generation antivenoms that can be produced more safely and cost effectively than current snakebite treatments.

Supported content

  1. Nature Genetics 52, 106–117 (2020). doi: 10.1038/s41588-019-0559-8

View the article on the Nature Index

See more research highlights from F. Hoffmann-La Roche AG

More research highlights from F. Hoffmann-La Roche AG

1 June 2019 - 31 May 2020

International vs. domestic collaboration by Share

  • 9.17% Domestic
  • 90.83% International

Note: Hover over the graph to view the percentage of collaboration.

Note: Collaboration is determined by the fractional count (Share), which is listed in parentheses.

Affiliated joint institutions and consortia

Return to institution outputs